Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Schwartz Investment Counsel Inc.

Schwartz Investment Counsel Inc. lifted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 100.0% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 800 shares of the biopharmaceutical company’s stock after acquiring an additional 400 shares during the period. Schwartz Investment Counsel Inc.’s holdings in Regeneron Pharmaceuticals were worth $570,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in REGN. CWM LLC boosted its stake in Regeneron Pharmaceuticals by 1.1% in the third quarter. CWM LLC now owns 2,272 shares of the biopharmaceutical company’s stock valued at $2,389,000 after acquiring an additional 25 shares in the last quarter. Ritholtz Wealth Management grew its stake in Regeneron Pharmaceuticals by 17.6% during the 3rd quarter. Ritholtz Wealth Management now owns 729 shares of the biopharmaceutical company’s stock worth $766,000 after buying an additional 109 shares during the last quarter. Creative Planning increased its position in Regeneron Pharmaceuticals by 22.7% during the third quarter. Creative Planning now owns 11,793 shares of the biopharmaceutical company’s stock worth $12,397,000 after buying an additional 2,178 shares during the period. Swedbank AB lifted its stake in Regeneron Pharmaceuticals by 10.1% in the third quarter. Swedbank AB now owns 149,363 shares of the biopharmaceutical company’s stock valued at $157,016,000 after buying an additional 13,705 shares during the last quarter. Finally, Magnus Financial Group LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 1.3% in the third quarter. Magnus Financial Group LLC now owns 1,588 shares of the biopharmaceutical company’s stock valued at $1,669,000 after acquiring an additional 20 shares during the period. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $665.46 on Wednesday. The firm’s fifty day simple moving average is $714.37 and its 200 day simple moving average is $906.38. The company has a current ratio of 4.73, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a twelve month low of $642.00 and a twelve month high of $1,211.20. The firm has a market capitalization of $73.13 billion, a price-to-earnings ratio of 17.38, a PEG ratio of 2.38 and a beta of 0.08.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. During the same quarter last year, the firm posted $11.86 earnings per share. The business’s quarterly revenue was up 10.3% on a year-over-year basis. As a group, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 36.67 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.53%. The ex-dividend date is Thursday, February 20th.

Analysts Set New Price Targets

REGN has been the subject of several research reports. Wolfe Research assumed coverage on shares of Regeneron Pharmaceuticals in a research report on Friday, November 15th. They issued an “outperform” rating and a $1,150.00 price target for the company. StockNews.com downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 4th. Canaccord Genuity Group assumed coverage on Regeneron Pharmaceuticals in a research report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target on the stock. Citigroup dropped their target price on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. Finally, Piper Sandler decreased their price target on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating for the company in a report on Monday, January 27th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $973.13.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.